Business Description
Swedish Orphan Biovitrum AB
ISIN : US8703212055
Share Class Description:
SWOBY: ADRCompare
Compare
Traded in other countries / regions
SOBI.Sweden0MTD.UKBIOVF.USAB6E.GermanySOBI.Mexico IPO Date
2023-03-07Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.54 | |||||
Debt-to-EBITDA | 2.63 | |||||
Interest Coverage | 3.09 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.18 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.5 | |||||
3-Year EBITDA Growth Rate | 1.1 | |||||
3-Year EPS without NRI Growth Rate | -2.5 | |||||
3-Year Book Growth Rate | 15.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 33.09 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.54 | |||||
9-Day RSI | 47.91 | |||||
14-Day RSI | 52.55 | |||||
6-1 Month Momentum % | 7.08 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.71 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.03 | |||||
Days Inventory | 254.68 | |||||
Days Sales Outstanding | 74.49 | |||||
Days Payable | 57.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.69 | |||||
Dividend Payout Ratio | 1.33 | |||||
Forward Dividend Yield % | 3.69 | |||||
5-Year Yield-on-Cost % | 3.69 | |||||
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | -20.4 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 76.34 | |||||
Operating Margin % | 17.29 | |||||
Net Margin % | 9.26 | |||||
FCF Margin % | 10.09 | |||||
ROE % | 6.68 | |||||
ROA % | 3.03 | |||||
ROIC % | 4.37 | |||||
ROC (Joel Greenblatt) % | 904.75 | |||||
ROCE % | 7.17 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 42.61 | |||||
Forward PE Ratio | 27.55 | |||||
PE Ratio without NRI | 34.82 | |||||
Shiller PE Ratio | 35.68 | |||||
Price-to-Owner-Earnings | 39.59 | |||||
PEG Ratio | 4.58 | |||||
PS Ratio | 3.91 | |||||
PB Ratio | 2.56 | |||||
Price-to-Free-Cash-Flow | 40.49 | |||||
Price-to-Operating-Cash-Flow | 19.28 | |||||
EV-to-EBIT | 28.43 | |||||
EV-to-Forward-EBIT | 22.01 | |||||
EV-to-EBITDA | 15.13 | |||||
EV-to-Forward-EBITDA | 12.63 | |||||
EV-to-Revenue | 4.77 | |||||
EV-to-Forward-Revenue | 4.61 | |||||
EV-to-FCF | 47.78 | |||||
Price-to-Projected-FCF | 2.2 | |||||
Price-to-DCF (Earnings Based) | 2.69 | |||||
Price-to-DCF (FCF Based) | 3.15 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Earnings Yield (Greenblatt) % | 3.52 | |||||
FCF Yield % | 2.52 | |||||
Forward Rate of Return (Yacktman) % | 5.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SWOBY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Swedish Orphan Biovitrum AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2,186.63 | ||
EPS (TTM) ($) | 0.305 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 52.55 | ||
14-Day ATR ($) | 0.027794 | ||
20-Day SMA ($) | 13.556 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 10 - 16.5 | ||
Shares Outstanding (Mil) | 679.74 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Swedish Orphan Biovitrum AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Swedish Orphan Biovitrum AB Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Swedish Orphan Biovitrum AB Frequently Asked Questions
What is Swedish Orphan Biovitrum AB(SWOBY)'s stock price today?
The current price of SWOBY is $13.55. The 52 week high of SWOBY is $16.50 and 52 week low is $10.00.
When is next earnings date of Swedish Orphan Biovitrum AB(SWOBY)?
The next earnings date of Swedish Orphan Biovitrum AB(SWOBY) is 2024-07-16.
Does Swedish Orphan Biovitrum AB(SWOBY) pay dividends? If so, how much?
The Dividend Yield %  of Swedish Orphan Biovitrum AB(SWOBY) is 3.69% (As of Today), Highest Dividend Payout Ratio of Swedish Orphan Biovitrum AB(SWOBY) was 1.33. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Swedish Orphan Biovitrum AB(SWOBY) is 3.69%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |